Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för tirapazamine. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

10 träffar

Bibliografisk träff 2014-02-01

Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer.

Trinkaus ME, Hicks RJ, Young RJ, Peters LJ, Solomon B, Bressel M, Corry J, Fisher R, Binns D, McArthur GA, Rischin D.

J Med Imaging Radiat Oncol · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/1754-9485.12155

Bibliografisk träff 2014-01-06

Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.

DiSilvestro PA, Ali S, Craighead PS, Lucci JA, Lee YC, Cohn DE, Spirtos NM, Tewari KS, Muller C, Gajewski WH, Steinhoff MM, Monk BJ.

J Clin Oncol · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1200/jco.2013.51.4265

Bibliografisk träff 2013-12-20

Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α.

Cai TY, Liu XW, Zhu H, Cao J, Zhang J, Ding L, Lou JS, He QJ, Yang B.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-13-0490

Bibliografisk träff 2013-08-13

The anticancer drug tirapazamine has antimicrobial activity against Escherichia coli, Staphylococcus aureus and Clostridium difficile.

Shah Z, Mahbuba R, Turcotte B.

FEMS Microbiol Lett · research support, non-u.s. gov't; journal article · DOI 10.1111/1574-6968.12223

Bibliografisk träff 2012-10-04

Is there a role for tirapazamine in the treatment of cervical cancer?

Ghatage P, Sabagh H.

Expert Opin Drug Metab Toxicol · systematic review; journal article · DOI 10.1517/17425255.2012.730518

Bibliografisk träff 2012-09-04

Usefulness of combined treatment with continuous administration of tirapazamine and mild temperature hyperthermia in γ-ray irradiation in terms of local tumour response and lung metastatic potential.

Masunaga S, Liu Y, Sakurai Y, Tanaka H, Suzuki M, Kondo N, Maruhashi A, Ono K.

Int J Hyperthermia · research support, non-u.s. gov't; journal article · DOI 10.3109/02656736.2012.714517

Bibliografisk träff 2012-05-15

Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca²⁺ balance protein levels.

Sliwinska J, Dudka J, Korga A, Burdan F, Matysiak W, Jodlowska-Jedrych B, Mandziuk S, Dawidek-Pietryka K.

Oxid Med Cell Longev · research-article; journal article · DOI 10.1155/2012/890826

Bibliografisk träff 2012-04-15

Enhanced antitumor efficacy of cisplatin by tirapazamine-transferrin conjugate.

Wu L, Wu J, Zhou Y, Tang X, Du Y, Hu Y.

Int J Pharm · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ijpharm.2012.04.032

Bibliografisk träff 2012-02-13

Effects of tirapazamine on experimental colorectal liver metastases after radiofrequency ablation.

Govaert KM, Nijkamp MW, Emmink BL, Steller EJ, Minchinton AI, Kranenburg O, Borel Rinkes IH.

Br J Surg · research support, non-u.s. gov't; journal article · DOI 10.1002/bjs.8668

Bibliografisk träff 1994-10-01

SR-4233 (Tirapazamine) acts as an uncoupler of oxidative phosphorylation in human MCF-7 breast carcinoma cells.

Ara G, Coleman CN, Teicher BA.

Cancer Lett · research support, u.s. gov't, p.h.s.; journal article · DOI 10.1016/0304-3835(94)90275-5